nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.12.2019 | Review

Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults

verfasst von: C. Betterle, F. Presotto, J. Furmaniak

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Addison’s disease (AD) is a rare disorder and among adult population in developed countries is most commonly caused by autoimmunity. In contrast, in children genetic causes are responsible for AD in the majority of patients.

Purpose

This review describes epidemiology, pathogenesis, genetics, natural history, clinical manifestations, immunological markers and diagnostic strategies in patients with AD. Standard care treatments including the management of patients during pregnancy and adrenal crises consistent with the recent consensus statement of the European Consortium and the Endocrine Society Clinical Practice Guideline are described. In addition, emerging therapies designed to improve the quality of life and new strategies to modify the natural history of autoimmune AD are discussed.

Conclusions

Progress in optimizing replacement therapy for patients with AD has allowed the patients to lead a normal life. However, continuous education of patients and health care professionals of ever-present danger of adrenal crisis is essential to save lives of patients with AD.

Eustachius B (1563) Opuscula anatomica de renum structura, efficio et administratione. In: Luchino V (ed) Venice

Addison T (1855) On the constitutional and local effects of disease of the supra-renal capsules. Samuel Highley, London

Trousseau A (1856) Bronze Addison’s disease. Arch Gen Med 8:478–485

Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223–243CrossRefPubMed

Cooper GS, Bynum MLK, Somers EC (2009) Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33:197–207CrossRefPubMedPubMedCentral

Betterle C, Scarpa R, Garelli S, Morlin L, Lazzarotto F, Presotto F, Coco G, Masiero S, Parolo A, Albergoni MP, Favero R, Barollo S, Salvà M, Basso D, Chen S, Rees Smith B, Furmaniak J, Mantero F (2013) Addison’s disease: a survey on 633 patients in Padova. Eur J Endocrinol 169:773–784CrossRefPubMed

Mason AS, Meade TW, Lee JA, Morris JN (1968) Epidemiological and clinical picture of Addison’s disease. Lancet 2:744–747CrossRefPubMed

Nerup J (1997) Addison’s disease-clinical studies. A report of 108 cases. Acta Endocrinol 76:121–141

Willis AC, Vince FP (1997) The prevalence of Addison’s disease in Coventry, UK. Postgrad Med J 73:286–288CrossRefPubMedPubMedCentral

10.

Kong MF, Jeffocoate W (1994) Eighty-six cases of Addison’s disease. Clin Endocrinol 41:757–761CrossRef

11.

Laureti S, Vecchi L, Santeusanio F, Falorni A (1999) Is the prevalence of Addison’s disease understimated? J Clin Endocrinol Metab 84:176–182

12.

Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, Fougner KJ, Berg TJ, Bollerslev J, Mella B, Carlson JA, Erlich H, Husebye ES (2009) Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 94:4882–4890CrossRefPubMed

13.

Björnsdottir S, Sundström A, Ludvigsson JF, Blomqvist P, Kämpe O, Bensing S (2013) Drug prescription patterns in patients with Addison’s disease: a Swedish population-based cohort study. J Clin Endocrinol Metab 98:2009–2018CrossRefPubMed

14.

Olafsson AS, Sigurjonsdottir HA (2016) Increasing prevalence of Addison’s disease. Results from a Nationwide study. Endocr Pract 22:30–35CrossRefPubMed

15.

Takayanagi R, Miura K, Nakagawa H, Nawata H (2000) Epidemiologic study of adrenal gland disorders in Japan. Biomed Pharmacother 54(Suppl 1):164s–168sCrossRefPubMed

16.

Chantzichristos D, Persson A, Björn Eliasson B, Miftaraj M, Franzén S, Svensson AM, Johannsson G (2018) Incidence, prevalence and seasonal onset variation of Addison’s disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies. Eur J Endocrinol 178:115–122CrossRef

17.

Guttman PH (1930) Addison’s disease: statistical analysis of 566 cases and study of the pathology. Arch Pathol 10:742–795

18.

Betterle C, Dal Prà C, Mantero F, Zanchetta R (2002) Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endo Rev 23:327–364CrossRef

19.

Dalin F, Nordling Eriksson G, Dahlqvist P, Hallgren Å, Wahlberg J, Ekwall O, Söderberg S, Rönnelid J, Olcén P, Winqvist O, Catrina SB, Kriström B, Laudius M, Isaksson M, Halldin Stenlid M, Gustafsson J, Gebre-Medhin G, Björnsdottir S, Janson A, Åkerman AK, Åman J, Duchen K, Bergthorsdottir R, Johannsson G, Lindskog E, Landin-Olsson M, Elfving M, Waldenström E, Hulting AL, Kämpe O, Bensing S (2017) Clinical and immunological characteristics of autoimmune addison disease: a nationwide Swedish multicenter study. J Clin Endocrinol Metab 102:379–389PubMed

20.

Falorni A, Minarelli V, Morelli S (2013) Therapy of adrenal insufficiency: an update. Endocrine 43:514–528CrossRefPubMed

21.

Cooper GS, Stroehla BC (2003) The epidemiology of autoimmune diseases. Autoimmun Rev 2:119–125CrossRefPubMed

22.

Ross I, Boulle A, Soule S, Levitt N, Pirie F, Karlsson A, Mienie J, Yang P, Wang H, She JX, Winter W, Schatz D (2010) Autoimmunity predominates in a large South African cohort with Addison’s disease of mainly European descent despite long-standing disease and is associated with HLA DQB*0201. Clin Endocrinol (Oxf) 73:291–298CrossRef

23.

Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C (2005) Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab 90:3243–3250CrossRefPubMed

24.

Guran T, Buonocore F, Saka N, Ozbek MN, Aycan Z, Bereket A, Bas F, Darcan S, Bideci A, Guven A, Demir K, Akinci A, Buyukinan M, Aydin BK, Turan S, Agladioglu SY, Atay Z, Abali ZY, Tarim O, Catli G, Yuksel B, Akcay T, Yildiz M, Ozen S, Doger E, Demirbilek H, Ucar A, Isik E, Ozhan B, Bolu S, Ozgen IT, Suntharalingham JP, Achermann JC (2016) Rare causes of primary adrenal insufficiency: genetic and clinical characterization of a large nationwide cohort. J Clin Endocrinol Metab 101:284–292CrossRefPubMed

25.

Charmandari E, Nicolaides NC, Chrousos GP (2014) Adrenal Insufficiency. Lancet 383:2152–2167CrossRefPubMed

26.

Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, Falorni A, Gan EH, Hulting AL, Kasperlik-Zaluska A, Kämpe O, Løvås K, Meyer G, Pearce SH (2014) Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 275:104–115CrossRefPubMed

27.

Leelarathna L, Breen L, Powrie JK, Thomas SM, Guzder R, McGowan B, Carroll PV (2010) Co-morbidities, management and clinical outcome of auto-immune Addison’s disease. Endocrine 38:113–117CrossRefPubMed

28.

Neufeld M, Blizzard RM, Polyglandular autoimmune disease (1980) In: Pinchera A, Doniach D, Fenzi GF, Baschieri L (eds) Symposium on autoimmune aspects of endocrine disorders. Academic Press, New York, pp 357–365

29.

Betterle C, Sabbadin C, Scaroni C, Presotto F. Autoimmune polyendocrine syndromes (APS) or multiple autoimmune syndromes (MAS) an overview. In: Polyendocrine disorders and endocrine neoplastic syndromes, pp 1–50. https://doi.org/10.1007/978-3-319-73082-0_1-1

30.

White PC (2016) Adrenocortical insufficiency. In: Nelson textbook of pediatrics, 20th edn. Elsevier, New York, pp 2703–2710

31.

Betterle C, Lazzarotto F, Presotto F (2004) Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol 137:225–233CrossRefPubMedPubMedCentral

32.

Betterle C, Garelli S, Salvà M (2015) La sindrome poliendocrina autoimmune di tipo 2 in Italia. l’Endocrinologo 16:68–76

33.

Husebye ES, Anderson MS, Kampe O (2018) Autoimmune polyendocrine syndromes. N Engl J Med 378:1132–1141CrossRefPubMedPubMedCentral

34.

Maclaren NK, Riley WJ (1986) Inherited susceptibility to autoimmune Addison’s disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type I autoimmune polyglandular syndrome. J Clin Endocrinol Metab 62:455–459CrossRefPubMed

35.

Myhre AG, Undlien DE, Løvås K, Uhlving S, Nedrebø BG, Fougner KJ, Trovik T, Sørheim JI, Husebye ES (2002) Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 87:618–623CrossRefPubMed

36.

Bratland E, Husebye ES (2011) Cellular immunity and immunopathology in autoimmune Addison’s disease. Mol Cell Endocrinol 336:180–190CrossRefPubMed

37.

Mitchell AL, Macarthur KD, Gan EH, Baggott LE, Wolff AS, Skinningsrud B, Platt H, Short A, Lobell A, Kämpe O, Bensing S, Betterle C, Kasperlik-Zaluska A, Zurawek M, Fichna M, Kockum I, Nordling Eriksson G, Ekwall O, Wahlberg J, Dahlqvist P, Hulting AL, Penna-Martinez M, Meyer G, Kahles H, Badenhoop K, Hahner S, Quinkler M, Falorni A, Phipps-Green A, Merriman TR, Ollier W, Cordell HJ, Undlien D, Czarnocka B, Husebye E, Pearce SH (2014) Association of autoimmune Addison’s disease with alleles of STAT4 and GATA3 in European cohorts. PLoS One 9:e88991 (Erratum in: PLoS One (2014) 9:e102428)

38.

Mitchell AL, Bøe Wolff A, MacArthur K, Weaver JU, Vaidya B; Swedish Addison Registry Study Group, Erichsen MM, Darlay R, Husebye ES, Cordell HJ, Pearce SH (2015) linkage analysis in autoimmune addison’s disease: NFATC1 as a potential novel susceptibility locus. PLoS One 10: e0123550. Erratum in: PLoS One (2015) 10:e0138844 (Sophie Bensing on behalf of The Swedish Addison Registry Study Group [corrected to Swedish Addison Registry Study Group])

39.

Falorni A, Brozzetti A, Perniola R (2016) From genetic predisposition to molecular mechanisms of autoimmune primary adrenal insufficiency. Front Horm Res 46:115–132CrossRefPubMed

40.

Ahonen P, Myllarniemi S, Sipila I, Perheentupa J (1990) Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 322:1829–1836CrossRefPubMed

41.

Perheentupa J (2006) Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 91:2843–2850CrossRefPubMed

42.

Husebye ES, Perheentupa J, Rautemaa R, Kämpe O (2009) Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 265:514–529CrossRefPubMed

43.

Cervato S, Mariniello B, Lazzarotto F, Morlin L, Zanchetta R, Radetti G, De Luca F, Valenzise M, Giordano R, Rizzo D, Giordano C, Betterle C (2009) Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clin Endocrinol (Oxf) 70:421–428CrossRef

44.

Bruserud O, Oftedal BE, Landegren N, Erichsen M, Bratland E, Lima K, Jorgensen AP, Myhre AG, Svartberg J, Fougner KJ, Bakke Å, Nedrebø BG, Mella B, Breivik L, Viken MK, Knappskog PM, Marthinussen MC, Løvås K, Kämpe O, Wolff AB, Husebye ES (2016) A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 101:2975–2983CrossRefPubMedPubMedCentral

45.

Betterle C, Salvà M, Sabbadin C, Garelli S (2016) La sindrome poliendocrina autoimmune di tipo 1 in Italia. l’Endocrinologo 17:10–20

46.

Wolff AS, Kärner J, Owe JF, Oftedal BE, Gilhus NE, Erichsen MM, Kämpe O, Meager A, Peterson P, Kisand K, Willcox N, Husebye ES (2014) Clinical and serologic parallels to APS-1 in patients with thymomas and autoantigen transcripts in their tumors. J Immunol 193:3880–3890CrossRefPubMed

47.

Kemp EH, Habibullah M, Kluger N, Ranki A, Sandhu HK, Krohn KJE, Weetman AP (2014) Prevalence and clinical associations of calcium-sensing receptor and NALP5 autoantibodies in Finnish APECED patients. J Clin Endocrinol Metab 99:1064–1071CrossRefPubMed

48.

Larosa MDP, Mackenzie R, Burne P, Garelli S, Barollo S, Masiero S, Rubin B, Chen S, Furmaniak J, Betterle C, Rees Smith B (2017) Assessment of autoantibodies to interferon-ω in patients with autoimmune polyendocrine syndrome type 1 using a new immunoprecipitation assay. Clin Chem Lab Med 55:1003–1012CrossRefPubMed

49.

De Martino L, Capalbo D, Improda N, D’Elia F, Di Mase R, D’Assante R, D’Acunzo I, Pignata C, Salerno M (2013) APECED: a paradigm of complex interactions between genetic background and susceptibility factors. Front Immunol 234:331

50.

Cetani F, Barbesino G, Borsari S, Pardi E, Cianferotti L, Pinchera A, Marcocci C (2001) A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly cosegregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 86:4747–4752CrossRefPubMed

51.

Oftedal BE, Hellesen A, Erichsen MM, Bratland E, Vardi A, Perheentupa J, Kemp EH, Fiskerstrand T, Viken MK, Weetman AP, Fleishman SJ, Banka S, Newman WG, Sewell WA, Sozaeva LS, Zayats T, Haugarvoll K, Orlova EM, Haavik J, Johansson S, Knappskog PM, Løvås K, Wolff AS, Abramson J, Husebye ES (2015) Dominant mutations in the Autoimmune Regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity 42:1185–1196CrossRefPubMed

52.

Capalbo D, Improda N, Esposito A, De Martino L, Barbieri F, Betterle C, Pignata C, Salerno M (2013) Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy from the pediatric perspective. J Endocrinol Invest 36:903–912PubMed

53.

Meloni A, Willcox N, Meager A, Atzeni M, Wolff AS, Husebye ES, Furcas M, Rosatelli MC, Cao A, Congia M (2012) Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients. Autoimmune Polyendocrine Syndrome Type 1: an extensive longitudinal study in Sardinian patients. J Clin Endocrinol Metab 97:1114–1124CrossRefPubMed

54.

Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:364–389CrossRefPubMed

55.

Drury MJ, Keelan DM, Timoney FJ, Irvine WJ (1979) Case report. Juvenile familial endocrinopathy. Clin Exp Immunol 7:125–132

56.

McNicol AM, Laidler P (1996) The adrenal gland and extra-adrenal paraganglia. In: Lewis PD (ed) Endocrine system. Churchill Livingstone, London, pp 59–114

57.

Skov J, Höijer J, Magnusson PKE, Ludvigsson JF, Kämpe O, Bensing S (2017) Heritability of Addison’s disease and prevalence of associated autoimmunity in a cohort of 112,100 Swedish twins. Endocrine 58:521–527CrossRefPubMedPubMedCentral

58.

Blizzard RM, Kyle MA, Chandler RW, Hung W (1962) Adrenal antibodies in Addison’s disease. Lancet 2:901–903CrossRefPubMed

59.

Baumann-Antczak A, Wedlock N, Bednarek J, Kiso Y, Krishnan H, Fowler S, Rees Smith B, Furmaniak J (1992) Autoimmune Addison’s disease and 21-hydroxylase. Lancet 340:429–430CrossRefPubMed

60.

Bednarek J, Furmaniak J, Wedlock N, Kiso Y, Baumann-Antczak A, Fowler S, Krishnan H, Craft JA, Rees Smith B (1992) Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison’s disease. FEBS Lett 309:51–55CrossRefPubMed

61.

Winqvist O, Karlsson FA, Kampe O (1992) 21-hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 339:1559–1562CrossRefPubMed

62.

Colls J, Betterle C, Rees Volpato M, Smith B, Furmaniak J (1995) A new immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in Addison’s disease. Clin Chem 41:375–380PubMed

63.

Falorni A, Nikoshkov A, Laureti S, Grenbäck E, Hulting AL, Casucci G, Santeusanio F, Brunetti P, Luthman H, Lernmark A (1995) High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radio binding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 80:2752–2755PubMed

64.

Tanaka H, Perez MS, Powell M, Sanders JF, Sawicka J, Chen S, Prentice L, Asawa T, Betterle C, Volpato M, Rees Smith B, Furmaniak J (1997) Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J Clin Endocrinol Metab 82:1440–1446PubMed

65.

Larosa MDP, Chen S, Steinmaus N, Macrae H, Guo L, Masiero S, Garelli S, Dalla Costa M, Bossowski A, Furmaniak J, Betterle C, Rees Smith B (2018) A new ELISA for autoantibodies to steroid 21-hydroxylase. Clin Chem Lab Med 56:933–938CrossRef

66.

Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, Furmaniak J, Bini V, Dotta F, Eisenbarth GS, Smith BR, Betterle C (2011) Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol 140:291–299CrossRefPubMed

67.

Falorni A, Bini V, Betterle C, Brozzetti A, Castaño L, Fichna M, Kämpe O, Mellgren G, Peterson P, Chen S, Rönnelid J, Seissler J, Tiberti C, Uibo R, Yu L, Lernmark Å, Husebye E (2015) Determination of 21-hydroxylase autoantibodies: inter-laboratory concordance in the EurAdrenal International Serum Exchange Program. Clin Chem Lab Med 53:1761–1770CrossRefPubMed

68.

Furmaniak J, Kominami S, Asawa T, Wedlock N, Colls J, Rees Smith B (1994) Autoimmune Addison’s disease-evidence for a role of steroid 21-hydroxylase autoantibodies in adrenal insufficiency. J Clin Endocrinol Metab 79:1517–1521PubMed

69.

Nikfarjam L, Kominami S, Yamazaki T, Chen S, Hewer R, Pra CD, Nakamatsu T, Betterle C, Zanchetta R, Rees Smith B, Furmaniak J (2005) Mechanism of inhibition of cytochrome P450 C21 enzyme activity by autoantibodies from patients with Addison’s disease. Eur J Endocrinol 152:95–101CrossRefPubMed

70.

Boscaro M, Betterle C, Volpato M, Fallo F, Furmaniak J, Rees Smith B, Sonino N (1996) Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. J Clin Endocrinol Metab 81:2801–2804PubMed

71.

Miguel RN, Chen S, Nikfarjam L, Kominami S, Carpenter B, Dal Prà C, Betterle C, Zanchetta R, Nakamatsu T, Powell M, Hewer R, Blundell TL, Rees Smith B, Furmaniak J (2005) Analysis of the interaction between human steroid 21-hydroxylase and various monoclonal antibodies using comparative structural modelling. Eur J Endocrinol 153:949–961CrossRefPubMed

72.

Pallan PS, Wang C, Lei L, Yoshimoto FK, Auchus RJ, Waterman MR, Guengerich FP, Egli M (2015) Human cytochrome p450 21a2, the major steroid 21-hydroxylase: structure of the enzyme progesterone substrate complex and rate-limiting C–H bond cleavage. J Biol Chem 290:13128–13143CrossRefPubMedPubMedCentral

73.

Betterle C, Dal Prà C, Pedini B, Zanchetta R, Albergoni MP, Chen S, Furmaniak J, Rees Smith B (2004) Assessment of adrenocortical function and autoantibodies in a baby born to a mother with autoimmune polyglandular syndrome Type 2. J Endocrinol Invest 27:618–621CrossRefPubMed

74.

Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM (2004) Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 199:1285–1291CrossRefPubMedPubMedCentral

75.

Husebye ES, Bratland E, Bredholt G, Fridkin M, Dayan M, Mozes E (2006) The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison’s disease, is an immunodominant T cell epitope. Endocrinology 147:2411–2416CrossRefPubMed

76.

Dawoodji A, Chen JL, Shepherd D, Dalin F, Tarlton A, Alimohammadi M, Penna-Martinez M, Meyer G, Mitchell AL, Gan EH, Bratland E, Bensing S, Husebye ES, Pearce SH, Badenhoop K, Kämpe O, Cerundolo V (2014) High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison’s disease patients. J Immunol 193:2118–2126CrossRefPubMed

77.

Betterle C, Sabbadin C, Garelli S, Dalla Costa M, Presotto F (2017) Malattie autoimmuni del surrene. In: Betterle C (ed) Le malattie autoimmuni, 2nd edn. Piccin, Padova, pp 145–166

78.

Betterle C, Zanette F, Zanchetta R, Pedini B, Trevisan A, Mantero F, Rigon F (1983) Complement-fixing adrenal autoantibodies as a marker for predicting onset of idiopathic Addison’s disease. Lancet 1:1238–1241CrossRefPubMed

79.

Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Greggio NA, Sanzari M, Tedesco F, Pedini B, Boscaro M, Presotto F (1997) I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J Clin Endocrinol Metab 82:932–938PubMed

80.

Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Zanchetta R, Greggio NA, Pedini B, Boscaro M, Presotto F (1997) II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison’s disease. J Clin Endocrinol Metab 82:939–942PubMed

81.

Falorni A, Laureti S, Nikoshkov A, Picchio ML, Hallengren B, Vandewalle CL, Gorus FK, Tortoioli C, Luthman H, Brunetti P, Santeusanio F (1997) 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison’s disease. Belgian Diabetes Registry. Clin Exp Immunol 107:341–346CrossRefPubMedPubMedCentral

82.

Laureti S, De Bellis A, Muccitelli VI, Calcinaro F, Bizzarro A, Rossi R, Bellastella A, Santeusanio F, Falorni A (1998) Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison’s disease. J Clin Endocrinol Metab 83:3507–3511PubMed

83.

Yu L, Brewer KW, Gates S, Wu A, Wang T, Babu SR, Gottlieb PA, Freed BM, Noble J, Erlich HA, Rewers MJ, Eisenbarth GS (1999) DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison’s disease. J Clin Endocrinol Metab 84:328–335PubMed

84.

Dal Prà C, Chen S, Furmaniak J, Rees Smith B, Pedini B, Moscon A, Zanchetta R, Betterle C (2003) Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison’s disease. Eur J Endocrinol 148:565–570

85.

Betterle C (2004) Addison’s Disease and Autoimmune Polyglandular Syndromes. In: Geenen V, Chrousos G (eds) Immunoendocrinology in health and disease. Marcel Dekker, New York, pp 491–536CrossRef

86.

Coco G, Dal Pra C, Presotto F, Albergoni MP, Canova C, Pedini B, Zanchetta R, Chen S, Furmaniak J, Rees Smith B, Mantero F, Betterle C (2006) Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 91:1637–1645CrossRefPubMed

87.

Betterle C, Garelli S, Presotto F, Furmaniak J (2016) From appearance of adrenal autoantibodies to clinical symptoms of Addison’s disease: natural history. In: Arvat E, Falorni A (eds) Cortisol excess and insufficiency. Karger, Horm Res Basel, pp 133–145CrossRef

88.

Betterle C, Scalici C, Presotto F, Pedini B, Moro L, Rigon F, Mantero F (1988) The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 117:467–475CrossRefPubMed

89.

Naletto L, Frigo AC, Ceccato F, Sabbadin C, Scarpa R, Presotto F, Dalla Costa M, Faggian D, Plebani M, Censi S, Manso J, Furmaniak J, Chen S, Rees Smith B, Masiero S, Pigliaru F, Boscaro M, Scaroni C, Betterle C (2019) The natural history of autoimmune Addison’s disease from the detection of autoantibodies to development of the disease: a long-term follow-up study on 143 patients. Eur J Endocrinol. https://doi.org/10.1530/eje-18-0313 CrossRefPubMed

90.

Baker PR, Nanduri P, Gottlieb PA, Yu L, Klingensmith GJ, Eisenbarth GS, Barker JM (2012) Predicting the onset of Addison’s disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf) 76:617–624CrossRef

91.

Manso J, Pezzani R, Scarpa R, Gallo N, Betterle C (2018) The natural history of autoimmune Addison’s disease with a non-classical presentation: a case report and review of literature. Clin Chem Lab Med 56:896–900CrossRefPubMed

92.

Lamand KY, Lo CY (2001) A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis. Clin Endocrinol 54:633–639CrossRef

93.

Upadhyay J, Sudhindra P, Abraham G, Trivedi N (2014) Tuberculosis of the adrenal gland: a case report and review of the literature of infections of the adrenal gland. Int J Endocrinol 2014:876037CrossRefPubMedPubMedCentral

94.

Slavin RE, Walsh TJ, Pollack AD (1980) Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine 59:352–366CrossRefPubMed

95.

Laway BA, Khan I, Shah BA, Choh NA, Bhat MA, Shah ZA (2013) Pattern of adrenal morphology and function in pulmonary tuberculosis: response to treatment with antitubercular therapy. Clin Endocrinol 79:321–325CrossRef

96.

Guo YK, Yang ZG, Li Y, Ma ES, Deng YP, Min PQ, Yin LL, Hu J, Zhang XC, Chen TW (2007) Addison’s disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation. Eur J Radiol 62:126–131CrossRefPubMed

97.

Alevritis EM, Sarubbi FA, Jordan RM, Peiris AN (2003) Infectious causes of adrenal insufficiency. Review article. South Med J 96:888–890CrossRefPubMed

98.

Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle-Vavra S, Daum RS (2005) Staphylococcus aureus sepsis and the Waterhouse–Friderichsen syndrome in children. N Engl J Med 353:1245–1251CrossRefPubMed

99.

Rajani K, Shapiro SR, Goetzman BW (1980) Adrenal abscess: complication of suppurative therapy of adrenal haemorrhage in the newborn. J Ped Surg 15:676–678CrossRef

100.

Atkinson GO, Kodroff MB, Gay BB, Ricketts RR (1985) Adrenal abscess in the neonate. Radiology 155:101–104CrossRefPubMed

101.

Agarwal J, Agarwal G, Ayyagari A, Kar DK, Mishra SK, Bhatia E (2001) Isolated Pneumocystis carinii infection of adrenal glands causing Addison’s disease in a non-immunocompromised adult. Endocr Pathol 12:87–91CrossRefPubMed

102.

Wheat J (1997) Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine 76:339–354CrossRefPubMed

103.

Chedid MF, Chedid AD, Geyer GR, Chedid MBF, Severo LC (2004) Histoplasmosis presenting as addisonian crisis in an immunocompetent host. Revista de Sociedade Brasiliera de Medicina Tropical 37:60–62CrossRef

104.

Wong P, Houston S, Power B, Laloe E, Bain VG (2001) A case of Histoplasma capsulatum causing granulomatous liver disease and Addisonian crisis. Can J Gastroenterol 15:687–691CrossRefPubMed

105.

Rimondi AP, Bianchini E, Barucchello G, Panzavolta R (1995) Addison’s disease caused by adrenal blastomycosis: a case refine needle aspiration (FNA) cytology. Cytopathology 6:277–279CrossRefPubMed

106.

Faical S, Borri ML, Hauache OM, Ajazen S (1996) Addison’s disease caused by Paracoccidioides brasiliensis: diagnosis by needle aspiration biopsy of the adrenal gland. Am J Roentgenol 166:461–462CrossRef

107.

Shah B, Taylor HC, Pillay I, Chuang-Park M, Dobrinich R (1986) Adrenal insufficiency due to cryptococcosis. JAMA 256:3247–3249CrossRefPubMed

108.

Takeshita A, Nakazawa H, Akiyama H, Takeuchi K, Kawai R, Oohashi K, Shishiba Y (1992) Disseminated crytococcosis presenting with adrenal insufficiency meningitides: resistant to prolonged antifungal therapy but responding to bilateral adrenalectomy. Intern Med 31:1401–1405CrossRefPubMed

109.

Spellberg BG, Filler SG, Edward JE (2006) Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42:244–251. https://doi.org/10.1086/499057 CrossRefPubMed

110.

Norbiato G, Bevilacqua M, Vago T, Baldi G, Chebat E, Bertora P, Moroni M, Galli M, Oldenburg N (1992) Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:608–613PubMed

111.

Opocher G, Mantero F (1994) Adrenal complications of HIV infection. Baillieres Clin Endocrinol Metab 8:769–776CrossRefPubMed

112.

Sokalski KM, Chu J, Mai AY, Qiu AQ, Albert AY, Zanet DL, Côté HC, Maan EJ, Pick N, Prior JC, Money DM, Murray MC (2016) CIHR team grant on HIV therapy and aging: CARMA. Endocrine abnormalities in HIV-infected women are associated with peak viral load—the children and women: antiretrovirals and markers of aging (CARMA) cohort. Clin Endocrinol 84:452–462CrossRef

113.

Ruiz-Palacios G, Pickering LK, van Eys J, Conklin R (1977) Disseminated herpes simplex with hepato-adrenal necrosis in a child with acute leucemia. J Pediatr 91:757–759CrossRefPubMed

114.

Danby P, Harris KP, Williams B, Feehally J, Walls J (1990) Adrenal dysfunction in patients with renal amyloidosis. Q J Med 76:915–922PubMed

115.

Arik N, Tasdemir I, Karaaslan Y, Yasavul U, Turgan C, Caglar S (1990) Subclinical adrenocortical insufficiency in renal amyloidosis. Subclinical adrenocortical insufficiency in renal amyloidosis. Nephron 56:246–248CrossRefPubMed

116.

El-Reshaid KA, Hakim AA, Hourani HA, Seshadri MS (1994) Endocrine abnormalities in patients with amyloidosis. Ren Fail 16:725–730CrossRefPubMed

117.

Falk RH, Comenzo R, Skinner M (1997) The systemic amyloidosis. N Engl J Med 337:898–909CrossRefPubMed

118.

Varkonyi J (2000) A case of non-HFE juvenile haemochromatosis presenting with adrenocortical insufficiency. Brit J Haematol 109:248–253CrossRef

119.

Doppman JL (2001) Adrenal Imaging. In: De Groot LJ, Jameson JL (eds) Endocrinology, 4th edn. Saunders Co., Philadelphia, pp 1747–1766

120.

Mayock RL, Bertrand P, Morrison CE, Scott JH (1963) Manifestations of sarcoidosis: analysis of 145 patients with a review of nine series selected from the literature. Am J Med 35:67–87CrossRefPubMed

121.

Walz B, From GLA (1990) Addison’s disease and sarcoidosis: unusual frequency of coexisting hypothyroidism (Schmidt’s syndrome). Am J Med 89:669–692CrossRef

122.

Watson JP, Lewis RA (1996) Schmidt’s syndrome associated with sarcoidosis. Postgrad Med J 72:435–436CrossRefPubMedPubMedCentral

123.

Papadopoulos KI, Hornblad Y, Liljebladh H, Hallegren B (1996) High frequency of endocrine autoimmune in patients with sarcoidosis. Eur J Endocrinol 134:331–336CrossRefPubMed

124.

Roucher-Boulez F, Mallet-Motak D, Samara-Boustani D, Jilani H, Ladjouze A, Souchon PF, Simon D, Nivot S, Heinrichs C, Ronze M, Bertagna X, Groisne L, Leheup B, Naud-Saudreau C, Blondin G, Lefevre C, Lemarchand L, Morel Y (2016) NNT mutations: a cause of primary adrenal insufficiency, oxidative stress and extra-adrenal defects. Eur J Endocrinol 175:73–84CrossRefPubMed

125.

Flück CE (2017) Update on pathogenesis of primary adrenal insufficiency: beyond steroid enzyme deficiency and autoimmune adrenal destruction. Eur J Endocrinol 177:99–111CrossRef

126.

Malikova JK, Flück CE (2014) Novel insight into etiology, diagnosis and management of primary adrenal insufficiency. Horm Res Paediatr 82:145–157CrossRefPubMed

127.

Vaidya B, Pearce S, Kendall-Taylor P (2000) Recent advances in the molecular genetics of congenital and acquired primary adrenocortical failure. Clin Endocrinol 53:403–418CrossRef

128.

Horn MA, Retterstøl L, Abdelnoor M, Skjeldal OH, Tallaksen CM (2013) Adrenoleukodystrophy in Norway: high rate of de novo mutations and age-dependent penetrance. Pediatr Neurol 48:212–219CrossRefPubMed

129.

Burtman E, Regelmann MO (2016) Endocrine dysfunction in X-linked adrenoleukodystrophy. Endocrinol Metab Clinics 45:295–309CrossRef

130.

Jadhav U, Harris RM, Jameson JL (2011) Hypogonadotropic hypogonadism in subjects with DAX1 mutations. Mol Cell Endocrinol 346:65–73CrossRefPubMedPubMedCentral

131.

Presotto F, Fornasini F, Betterle C, Federspil G, Rossato M (2005) Acute adrenal failure as the heralding symptom of primary antiphospholipid syndrome: report of a case and review of the literature. Eur J Endocrinol 153:507–514CrossRefPubMed

132.

Kamenický P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, Brailly-Tabard S, Leboulleux S, Schlumberger M, Baudin E, Chanson P, Young J (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 96:2796–2804CrossRefPubMed

133.

Fonseca V, Brown R, Hochhauser D, Ginsburg J, Havard CW (1986) Acute adrenal crisis precipitated by thyroxine. Br Med J (Clin Res Ed) 292:1185–1186CrossRef

134.

Seckl JR, Chapman KE (1997) Medical and physiological aspects of the 11 beta-hydroxysteroid dehydrogenase system. Eur J Biochem 249:361–364CrossRefPubMed

135.

Lodish MB (2013) Kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab 98:1333–1342CrossRefPubMedPubMedCentral

136.

Abdel-Rahman O, El Halawani H, Mona Fouad M (2016) Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol 12:413–425CrossRefPubMed

137.

Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, Nachtigall L (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99:4078–4085CrossRefPubMed

138.

Hescot S, Haissaguerre M, Pautier P, Kuhn E, Schlumberger M, Berdelou A (2018) Immunotherapy-induced Addison’s disease: a rare, persistent and potentially lethal side-effect. Eur J Cancer 97:57–58CrossRefPubMed

139.

Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM (2015) Adrenal Insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100:2171–2180CrossRefPubMed

140.

Løvås K, Husebye ES (2002) High prevalence and increasing incidence of Addison’s disease in western Norway. Clin Endocrinol (Oxf) 56:787–791CrossRef

141.

Rashidi A, Fisher SI (2013) Primary adrenal lymphoma: a systematic review. Ann Hematol 92:1583–1593CrossRefPubMed

142.

Ten S, New M, Maclaren N (2001) Clinical review 130: Addison’s disease 2001. J Clin Endocrinol Metab 86:2909–2922PubMed

143.

Brandão Neto RA, de Carvalho JF (2014) Diagnosis and classification of Addison’s disease (autoimmune adrenalitis). Autoimmun Rev 89:408–411CrossRef

144.

Armstrong L, Bell PM (1996) Addison’s disease presented as reduced insulin requirement in insulin dependent diabetes. Br Med J 312:1601–1602CrossRef

145.

Saevik ÅB, Åkerman AK, Grønning K, Nermoen I, Valland SF, Finnes TE, Isaksson M, Dahlqvist P, Bergthorsdottir R, Ekwall O, Skov J, Nedrebø BG, Hulting AL, Wahlberg J, Svartberg J, Höybye C, Bleskestad IH, Jørgensen AP, Kämpe O, Øksnes M, Bensing S, Husebye ES (2017) Clues for early detection of autoimmune Addison’s disease-myths and realities. J Int Med. https://doi.org/10.1111/joim.12699 CrossRef

146.

Kanczkowski W, Sue M, Bornstein SR (2016) Adrenal gland microenvironment and its involvement in the regulation of stress-induced hormone secretion during sepsis. Front Endocrinol 7:156. https://doi.org/10.3389/fendo.2016.00156 CrossRef

147.

Allolio B (2015) Extensive expertise in endocrinology: adrenal crisis. Eur J Endocrinol 172:R115–R124CrossRefPubMed

148.

Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K, Milovanovic D, Beuschlein F, Willenberg HS, Quinkler M, Allolio B (2015) High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 100:407–416CrossRefPubMed

149.

Meyer G, Badenhoop K, Linder R (2016) Addison’s disease with polyglandular autoimmunity carries a more than 2.5-fold risk for adrenal crises: German Health insurance data 2010–2013. Clin Endocrinol (Oxf) 85:347–353CrossRef

150.

Reato G, Morlin L, Chen S, Furmaniak J, Smith BR, Masiero S, Albergoni MP, Cervato S, Zanchetta R, Betterle C (2011) Premature ovarian failure in patients with autoimmune Addison’s disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab 96:E1255–E1261CrossRefPubMed

151.

Hoek A, Schoemaker J, Drexage HA (1997) Premature ovarian failure and ovarian autoimmunity. Endocrine Rev 18:107–134

152.

Erichsen MM, Husebye ES, Michelsen TM, Dahl AA, Løvås K (2010) Sexuality and fertility in women with Addison’s disease. J Clin Endocrinol Metab 95:4354–4360CrossRefPubMed

153.

Granata A, Tirabassi G, Pugni V, Arnaldi G, Boscaro M, Carani C, Balercia G (2013) Sexual dysfunctions in men affected by autoimmune Addison’s disease before and after short-term gluco- and mineralocorticoid replacement therapy. J Sex Med 2036–2043

154.

Barthel A, Benker G, Berens K, Diederich S, Manfras B, Gruber M, Kanczkowski W, Kline G, Kamvissi-Lorenz V, Hahner S, Beuschlein F, Brennand A, Boehm BO, Torpy DJ, Bornstein ST (2019) An Update on Addison’s Disease. Exp Clin Endocrinol Diabetes 127:165–170CrossRefPubMed

155.

Struja T, Briner L, Meier A, Kutz A, Mundwiler E, Huber A, Mueller B, Bernasconi L, Schuetz P (2017) Diagnostic accuracy of basal cortisol level to predict adrenal insufficiency in cosyntropin testing: results from an observational cohort study with 804 patients. Endocr Pract 23:949–961CrossRefPubMed

156.

Hangaard J, Andersen M, Grodum E, Koldkjaer O, Hagen C (1996) Pulsatile thyrotropin secretion in patients with Addison’s disease during variable glucocorticoid therapy. J Clin Endocrinol Metab 81:2502–2507PubMed

157.

Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, Manji N, Allahabadia A, Armitage M, Chatterjee KV, Lazarus JH, Pearce SH, Vaidya B, Gough SC, Franklyn JA (2010) Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 123:183.e1–183.e9CrossRef

158.

Wiebolt J, Achterbergh R, den Boer A, van der Leij S, Marsch E, Suelmann B, de Vries R, van Haeften TW (2011) Clustering of additional autoimmunity behaves differently in Hashimoto’s patients compared with Graves’ patients. Eur J Endocrinol 164:789–794CrossRefPubMed

159.

Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Beck-Peccoz P, Bizzarro A, Dotta F, Mantero F, Bellastella A, Betterle C, Santeusanio F (2004) SIE Addison Study Group. Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab 89:1598–1604CrossRefPubMed

160.

Ramon I, Mathian A, Bachelot A, Hervier B, Haroche J, Boutin-Le Thi Huong D, Costedoat-Chalumeau N, Wechsler B, Karmali R, Velkeniers B, Touraine P, Coussieu C, Bennani A, Renard-Penna R, Grenier PA, Wahl D, Piette JC, Amoura Z (2013) Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab 98:3179–3189CrossRefPubMed

161.

Langlois F, Lim DST, Fleseriu M (2017) Update on adrenal insufficiency: diagnosis and management in pregnancy. Curr Opin Endocrinol Diabetes Obes 24:184–192CrossRefPubMed

162.

Schneiderman M, Czuzoj-Shulman N, Spence AR, Abenhaim HA (2017) Maternal and neonatal outcomes of pregnancies in women with Addison’s disease: a population-based cohort study on 7.7 million births. BJOG 124:1772–1779CrossRefPubMed

163.

Lebbe M, Arlt W (2013) What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol 78:497–502CrossRef

164.

Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL (1991) Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 72:39–45CrossRefPubMed

165.

Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM, De Bruin R (1998) The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab 83:1247–1252PubMed

166.

Johannsson G, Falorni A, Skrtic S, Lennernäs H, Quinkler M, Monson JP, Stewart PM (2015) Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 82:2–11CrossRef

167.

Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S (2009) Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 161:119–130CrossRefPubMed

168.

Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473–481CrossRefPubMed

169.

Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Øksnes M (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172:619–626CrossRefPubMed

170.

Johannsson G, Lennernäs H, Marelli C, Rockich K, Skrtic S (2016) Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. Eur J Endocrinol 175:85–93CrossRefPubMedPubMedCentral

171.

Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, Karamouzis I, Lucchiari M, Manetta T, Mengozzi G, Arvat E, Ghigo E (2016) Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51:360–368CrossRefPubMed

172.

Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A (2018) Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6:173–185CrossRefPubMed

173.

Guarnotta V, Ciresi A, Pillitteri G, Giordano C (2018) Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin Endocrinol 88:665–672CrossRef

174.

Ceccato F, Selmin E, Sabbadin C, Miriam Costa M, Antonelli G, Plebani M, Barbot M, Betterle C, Boscaro M, Scaroni C (2018) Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocrine Connect 7:965–974CrossRef

175.

Boesen VB, Christoffersen T, Watt T, Borresen SW, Klose M, Feldt-Rasmussen U (2018) PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open 8:e019487PubMedPubMedCentral

176.

Whitaker M, Debono M, Huatan H, Merke D, Arlt W, Ross RJ (2014) An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf) 80:554–561CrossRef

177.

Verma S, Vanryzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, Calis KA, Arlt W, Ross RJ, Merke DP (2010) A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 72:441–447CrossRef

178.

Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, Daley LA, Ling A, Liu CY, Soldin SJ, Merke DP (2016) A phase 2 study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia. J Clin Endocrinol Metab 101:4690–4698CrossRefPubMedPubMedCentral

179.

Jones CM, Mallappa A, Reisch N, Nikolaou N, Krone N, Hughes BA, O’Neil DM, Whitaker MJ, Tomlinson JW, Storbeck KH, Merke DP, Ross RJ, Arlt W (2017) Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. J Clin Endocrinol Metab 102:1797–1806PubMed

180.

Reznik Y (2016) Therapeutic innovations in endocrine diseases. Part 2: modified-release glucocorticoid compounds: what good do they provide to the adrenal insufficient patient? Presse Med 45:e205–e210CrossRefPubMed

181.

Whitaker MJ, Spielmann S, Digweed D, Huatan H, Eckland D, Johnson TN, Tucker G, Krude H, Blankenstein O, Ross RJ (2015) Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. J Clin Endocrinol Metab 100:1681–1688CrossRefPubMed

182.

Neumann U, Whitaker MJ, Wiegand S, Krude H, Porter J, Davies M, Digweed D, Voet B, Ross RJ, Blankenstein O (2018) Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clin Endocrinol (Oxf) 88:21–29CrossRef

183.

Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ (2006) Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 65:45–50CrossRef

184.

Løvås K, Husebye ES (2007) Continuous subcutaneous hydrocortisone infusion in Addison’s disease. Eur J Endocrinol 157:109–112CrossRefPubMed

185.

Burger-Stritt S, Bachmann L, Kurlbaum M, Hahner S (2019) Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison’s disease. Endocrine Connect 8:425–434CrossRef

186.

Esposito D, Pasquali D, Johannsson G (2018) Primary adrenal insufficiency: managing mineralocorticoid replacement therapy. J Clin Endocrinol Metab 103:376–387CrossRefPubMed

187.

Schultebraucks K, Wingenfeld K, Otte C, Quinkler M (2016) The role of fludrocortisone in cognition and mood in patients with primary adrenal insufficiency (Addison’s disease). Neuroendocrinology 103:315–320CrossRefPubMed

188.

Quinkler M, Dahlqvist P, Husebye ES, Kämpe OA (2015) European Emergency Card for adrenal insufficiency can save lives. Eur J Intern Med 26:75–76CrossRefPubMed

189.

Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B (1994) Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 219:416–425CrossRefPubMedPubMedCentral

190.

Khoo B, Boshier PR, Freethy A, Tharakan G, Saeed S, Hill N, Williams EL, Moorthy K, Tolley N, Jiao LR, Spalding D, Palazzo F, Meeran K, Tan T (2017) Redefining the stress cortisol response to surgery. Clin Endocrinol 87:451–458CrossRef

191.

Prete A, Yan Q, Al-Tarrah K, Akturk HK, Prokop LJ, Alahdab F, Foster MA, Lord JM, Karavitaki N, Wass JA, Murad MH, Arlt W, Bancos I (2018) The cortisol stress response induced by surgery: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 89:554–567CrossRef

192.

Simunkova K, Jovanovic N, Rostrup E, Methlie P, Øksnes M, Nilsen RM, Hennø H, Tilseth M, Godang K, Kovac A, Løvås K, Husebye ES (2016) Effect of a pre-exercise hydrocortisone dose on short-term physical performance in female patients with primary adrenal failure. Eur J Endocrinol 174:97–105CrossRefPubMed

193.

Napier C, Pearce SHS (2012) Autoimmune Addison’s disease. La Presse Médicale 41:e626–e635CrossRefPubMed

194.

Wass JAH, Arlt W (2012) How to avoid precipitating an acute adrenal crisis. BMJ 345:e6333CrossRefPubMed

195.

Hahner S, Burger-Stritt S, Allolio B (2013) Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol 169:147–154CrossRefPubMed

196.

De Bellis A, Bizzarro A, Rossi R, Paglionico VA, Criscuolo T, Lombardi G, Bellastella A (1993) Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 76:1002–1007PubMed

197.

De Bellis AM, Falorni A, Laureti S, Perrino S, Coronella C, Forini F, Bizzarro E, Bizzarro A, Abbate G, Bellastella A (2001) Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J Clin Endocrinol Metab 86:675–678CrossRef

198.

Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P (2009) Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 131:360–365CrossRefPubMed

199.

El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH (2009) Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130:252–258CrossRefPubMed

200.

Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–352CrossRefPubMed

201.

Nelson A, Dhimolea E, Rechert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Disc 9:767–774CrossRef

202.

Yu L, Herold K, Krause-Steinrauf H, McGee PL, Bundy B, Pugliese A, Krischer J, Eisenbarth GS (2011) Type 1 Diabetes Trial Net Anti-CD20 Study Group. Rituximab selectively suppresses specific islet antibodies. Diabetes 60:2560–2565CrossRefPubMedPubMedCentral

203.

Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P (2012) Small dose of rituximab for Graves’ orbitopathy: new insights into the mechanism of action. Arch Ophthalmol 130:122–124CrossRefPubMed

204.

Pearce SH, Mitchell AL, Bennett S, King P, Chandran S, Nag S, Chen S, Rees Smith B, I’aacs JD, Vaidya B (2012) Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison’s disease. J Clin Endocrinol Metab 97:E1927–E1932CrossRefPubMedPubMedCentral

205.

Gan EH, Pearce SH (2017) Management of endocrine disease: regenerative therapies in autoimmune Addison’s disease. Eur J Endocrinol 176:R123–R135CrossRefPubMed

206.

Gan EH, MacArthur K, Mitchell AL, Hughes BA, Perros P, Ball SG, James RA, Quinton R, Chen S, Furmaniak J, Arlt W, Pearce SH (2014) Residual adrenal function in autoimmune Addison’s disease: improvement after tetracosactide (ACTH 1-24) treatment. J Clin Endocrinol Metab 99:111–118CrossRefPubMed

207.

Løvås K, Curran S, Oksnes M, Husebye ES, Huppert FA, Chatterjee VK (2010) Development of a disease-specific quality of life questionnaire in Addison’s disease. J Clin Endocrinol Metab 95:545–551CrossRefPubMed

208.

Øksnes M, Bensing S, Hulting AL, Kämpe O, Hackemann A, Meyer G, Badenhoop K, Betterle C, Parolo A, Giordano R, Falorni A, Papierska L, Jeske W, Kasperlik-Zaluska AA, Chatterjee VK, Husebye ES, Løvås K (2012) Quality of life in European patients with Addison’s disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 97:568–576CrossRefPubMed

209.

Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G (2006) Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 91:4849–4853CrossRefPubMed

210.

Bensing S, Brandt L, Tabaroj F, Sjöberg O, Nilsson B, Ekbom A, Blomqvist P, Kämpe O (2008) Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 69:697–704CrossRef

211.

Erichsen MM, Løvås K, Fougner KJ, Svartberg J, Hauge ER, Bollerslev J, Berg JP, Mella B, Husebye ES (2009) Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol 160:233–237CrossRefPubMed

212.

Chantzichristos D, Persson A, Eliasson B, Miftaraj M, Franzén S, Bergthorsdottir R, Gudbjörnsdottir S, Svensson AM, Johannsson G (2017) Mortality in patients with diabetes mellitus and Addison’s disease: a nationwide, matched, observational cohort study. Eur J Endocrinol 176:31–39CrossRefPubMed

Titel: Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults
verfasst von: C. Betterle
F. Presotto
J. Furmaniak
Publikationsdatum: 01.12.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 12/2019
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-019-01079-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Purpose

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Transoral thyroidectomy: new method with new complications’ spectrum

Overview of results from the Vitamin D Assessment (ViDA) study

High rate of detection of ultrasound signs of prostatitis in patients with HPV-DNA persistence on semen: role of ultrasound in HPV-related male accessory gland infection

p38MAPK controls fibroblast growth factor 23 (FGF23) synthesis in UMR106-osteoblast-like cells and in IDG-SW3 osteocytes

Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors